CXCL10 is a crucial chemoattractant for efficient intranasal delivery of mesenchymal stem cells to the neonatal hypoxic-ischemic brain
Authors:
Open Access
- 7 May 2024
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 15 (1) , 1-16
Abstract
Background: Hypoxic-Ischemic Encephalopathy (HIE) is a leading cause of mortality and morbidity in newborns. Recent research has shown promise in using intranasal mesenchymal stem cell (MSC) therapy if administered within 10 days after Hypoxia-Ischemia (HI) in neonatal mice. MSCs migrate from the nasal cavity to the cerebral lesion in response to chemotactic cues. Which exact chemokines are crucial for MSC guidance to the HI lesion is currently not fully understood. This study investigates the role of CXCL10 in MSC migration towards the HI-injured brain. Methods: HI was induced in male and female 9-day-old C57BL/6 mice followed by intranasal MSC treatment at day 10 or 17 post-HI. CXCL10 protein levels, PKH26-labeled MSCs and lesion size were assessed by ELISA, immunofluorescent imaging and MAP2 staining respectively. At day 17 post-HI, when CXCL10 levels were reduced, intracranial CXCL10 injection and intranasal PKH26-labeled MSC administration were combined to assess CXCL10-guided MSC migration. MSC treatment efficacy was evaluated after 18 days, measuring lesion size, motor outcome (cylinder rearing task), glial scarring (GFAP staining) and neuronal density (NeuN staining) around the lesion. Expression of the receptor for CXCL10, i.e. CXCR3, on MSCs was confirmed by qPCR and Western Blot. Moreover, CXCL10-guided MSC migration was assessed through an in vitro transwell migration assay. Results: Intranasal MSC treatment at day 17 post-HI did not reduce lesion size in contrast to earlier treatment timepoints. Cerebral CXCL10 levels were significantly decreased at 17 days versus 10 days post-HI and correlated with reduced MSC migration towards the brain. In vitro experiments demonstrated that CXCR3 receptor inhibition prevented CXCL10-guided migration of MSCs. Intracranial CXCL10 injection at day 17 post-HI significantly increased the number of MSCs reaching the lesion which was accompanied by repair of the HI lesion as measured by reduced lesion size and glial scarring, and an increased number of neurons around the lesion. Conclusions: This study underscores the crucial role of the chemoattractant CXCL10 in guiding MSCs to the HI lesion after intranasal administration. Strategies to enhance CXCR3-mediated migration of MSCs may improve the efficacy of MSC therapy or extend its regenerative therapeutic window.Keywords
Funding Information
- ZonMw (116002003)
This publication has 63 references indexed in Scilit:
- Intranasal mesenchymal stem cell therapy to boost myelination after encephalopathy of prematurityGlia, 2020
- Pathophysiology of hypoxic–ischemic encephalopathy: a review of the past and a view on the futureActa Neurologica Belgica, 2020
- CCL2 andCXCL10 are associated with poor outcome after intracerebral hemorrhageAnnals of Clinical and Translational Neurology, 2018
- Home sweet home: the neural stem cell niche throughout development and after injuryCell and tissue research, 2017
- Hypothermia for Neonatal Hypoxic Ischemic EncephalopathyArchives of Pediatrics & Adolescent Medicine, 2012
- Mesenchymal stem cells restore cortical rewiring after neonatal ischemia in miceAnnals of Neurology, 2012
- CXCL10/CXCR3 signaling in glia cells differentially affects NMDA‐induced cell death in CA and DG neurons of the mouse hippocampusHippocampus, 2011
- Comparative Analysis of Chemokine Receptor's Expression in Mesenchymal Stem Cells Derived from Human Bone Marrow and Adipose TissueJournal of Molecular Neuroscience, 2010
- Sustained neocortical neurogenesis after neonatal hypoxic/ischemic injuryAnnals of Neurology, 2007
- Neutralization of the chemokine CXCL10 reduces apoptosis and increases axon sprouting after spinal cord injuryJournal of Neuroscience Research, 2006